OTCMKTS:ARTH Arch Therapeutics (ARTH) Stock Forecast, Price & News $3.10 0.00 (0.00%) (As of 05/30/2023 ET) Add Compare Share Share Today's Range$3.10▼$3.1050-Day Range$2.35▼$4.9052-Week Range$2.02▼$12.00Volume41 shsAverage Volume415 shsMarket Capitalization$4.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest Arch Therapeutics MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.03) to $14.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.10 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Arch Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.02% of the outstanding shares of Arch Therapeutics have been sold short.Short Interest Ratio / Days to CoverArch Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arch Therapeutics has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArch Therapeutics does not currently pay a dividend.Dividend GrowthArch Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARTH. Previous Next 2.3 News and Social Media Coverage News SentimentArch Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Arch Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Arch Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arch Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.68% of the stock of Arch Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.01% of the stock of Arch Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arch Therapeutics are expected to grow in the coming year, from ($0.03) to $14.47 per share. Previous Next See Top Rated MarketRank™ Stocks Here About Arch Therapeutics (OTCMKTS:ARTH) StockArch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.Read More Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTH Stock News HeadlinesMay 27, 2023 | americanbankingnews.comShort Interest in Arch Therapeutics, Inc. (OTCMKTS:ARTH) Rises By 100.0%May 18, 2023 | americanbankingnews.comArch Therapeutics (OTCMKTS:ARTH) Stock Price Passes Below Fifty Day Moving Average of $3.30May 31, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.April 25, 2023 | finance.yahoo.comArch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)April 16, 2023 | americanbankingnews.comArch Therapeutics, Inc. (OTCMKTS:ARTH) Short Interest UpdateApril 5, 2023 | finance.yahoo.comDedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In EffectMarch 20, 2023 | investing.comArch Therapeutics Inc (ARTHD)March 9, 2023 | finance.yahoo.comArch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid ServicesMay 31, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.March 7, 2023 | finance.yahoo.comArch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government FacilitiesFebruary 23, 2023 | benzinga.comArch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and RevenueJanuary 24, 2023 | msn.comWound products developer Arch Therapeutics files for uplisting, $35M offering (update)January 18, 2023 | finanznachrichten.deArch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeJanuary 18, 2023 | finance.yahoo.comArch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound SystemJanuary 17, 2023 | finance.yahoo.comArch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National ExchangeDecember 5, 2022 | finance.yahoo.comThe Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound SystemOctober 20, 2022 | seekingalpha.comARTH Arch Therapeutics, Inc.October 18, 2022 | yahoo.comKey Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) FallOctober 11, 2022 | finance.yahoo.comArch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) FallSeptember 23, 2022 | finance.yahoo.comArch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support ProgramSeptember 16, 2022 | finance.yahoo.comArch Therapeutics Announces Intent to Uplist from OTC to a National ExchangeSeptember 7, 2022 | finance.yahoo.comArch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound SystemJuly 14, 2022 | benzinga.comArch Therapeutics (OTC:ARTH), Short Interest ReportJuly 7, 2022 | finance.yahoo.comArch Therapeutics Raises Approximately $3.5 Million in Convertible Note FinancingJune 22, 2022 | finance.yahoo.comArch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling ChannelMay 9, 2022 | finance.yahoo.comArch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC SpringMay 9, 2022 | benzinga.comArch Therapeutics' Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC SpringSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ARTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ARTH Company Calendar Last Earnings7/23/2020Today5/31/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ARTH Previous SymbolNASDAQ:ARTH CUSIPN/A CIK1537561 Webwww.archtherapeutics.com Phone(617) 431-2313FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,280,000.00 Net Margins-18,293.00% Pretax Margin-18,289.75% Return on EquityN/A Return on Assets-239.38% Debt Debt-to-Equity RatioN/A Current Ratio0.20 Quick Ratio0.02 Sales & Book Value Annual Sales$20,000.00 Price / Sales199.95 Cash FlowN/A Price / Cash FlowN/A Book Value($3.36) per share Price / Book-0.92Miscellaneous Outstanding Shares1,290,000Free Float1,161,000Market Cap$4.00 million OptionableNot Optionable Beta0.71 Key ExecutivesTerrence W. NorchiChairman, President & Chief Executive OfficerMichael S. AbramsChief Financial Officer & TreasurerDaniel M. YrigoyenVice President-SalesKey CompetitorsBluejay DiagnosticsNASDAQ:BJDXInVivo TherapeuticsNASDAQ:NVIVINVO BioscienceNASDAQ:INVOSigyn TherapeuticsOTCMKTS:SIGYDynatronicsNASDAQ:DYNTView All Competitors ARTH Stock - Frequently Asked Questions How have ARTH shares performed in 2023? Arch Therapeutics' stock was trading at $0.0260 at the beginning of the year. Since then, ARTH shares have increased by 11,823.1% and is now trading at $3.10. View the best growth stocks for 2023 here. Are investors shorting Arch Therapeutics? Arch Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 200 shares, an increase of 100.0% from the April 30th total of 100 shares. Based on an average trading volume of 1,200 shares, the short-interest ratio is currently 0.2 days. View Arch Therapeutics' Short Interest. How were Arch Therapeutics' earnings last quarter? Arch Therapeutics, Inc. (OTCMKTS:ARTH) issued its quarterly earnings data on Thursday, July, 23rd. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. What other stocks do shareholders of Arch Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH). What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How do I buy shares of Arch Therapeutics? Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $3.10. How much money does Arch Therapeutics make? Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $4.00 million and generates $20,000.00 in revenue each year. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com. This page (OTCMKTS:ARTH) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arch Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.